Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM16390 as a Single Agent and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT06724016Phase 1Recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Jul 2031
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of HM16390 in solid tumor (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Dose-Limiting Toxicities at 21 days and Adverse Events. Started Dec 2024; status: recruiting.
02
Drugs
HM16390
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06724016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724016.